Lack of appetite and weight loss are a common side effect of ADHD therapy with amphetamines such as methylphenidate. Lack of sufficient food intake has been shown to have negative effects on weight and height as well as learning and memory. There is no current treatment to prevent this loss of appetite except discontinuation or reduction of the methylphenidate. Discontinuation or reduction of the drug can cause the return of ADHD symptoms. The purpose of this study is to compare the effects, good and/or bad, of two doses of a drug, cyproheptadine, vs placebo to find out if cyproheptadine prevents the appetite suppression associated with methylphenidate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
99
Watson generic, starting dose 18mg QD
cyproheptadine hydrochloride
SMRI (Schuster Medical Research Institute)
Van Nuys, California, United States
Appetite - Appetite and Dietary Assessment Tool (ADAT) developed by Burrowes et al (1996)
Time frame: 0, 12 weeks
Swanson, Nolan & Pelham Rating Scale - Revised (SNAP-IV): ADHD Combined Score
The items from the DSM-IV (1994) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD) are included for the two subsets of symptoms: inattention (items #1-#9) and hyperactivity/ impulsivity (items #11-#19).
Time frame: 0,1,5,9,12 weeks
Weight
Time frame: 0,1,5,9,12 Weeks
Appetite - VAS - Visual Analogue Scale
Time frame: 0,1,5,9,12
Clinical Global Impressions - Improvement(CGI-I): ADHD Score
Time frame: 1,5,9,12 weeks
Clinical Global Impressions - Severity(CGI-S): ADHD Score
Time frame: 0,1,5,9,12
Clinical Global Impressions - Effectiveness(CGI-E): ADHD Score
Time frame: 1,5,9,12
Appetite - Appetite and Dietary Assessment Tool (ADAT) developed by Burrowes et al (1996)
Time frame: 1,5,9 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.